Dr Kathleen Pishas
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
19 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status
DOI: 10.3390/ijms270417742024
Journal article
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma
DOI: 10.1038/s41597-024-03869-x2024
Journal article
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
DOI: 10.1158/1078-0432.CCR-23-35522023
Journal article
Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.
DOI: 10.1101/2023.11.09.232983212023
Journal article
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme
DOI: 10.1111/his.149062023
Journal article
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer
DOI: 10.1038/s41588-023-01320-22018
Research Grant
Pre-Clinical Evaluation of the Lsd1 Inhibitor Hci-2509: Defining the Biomarkers of Sensitivity and the Mechanisms of Resistance
RECENT SCHOLARLY WORKS
2022
Journal article
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
DOI: 10.1038/s41698-022-00288-22022
Journal article
Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma
DOI: 10.1158/1541-7786.MCR-22-00272021
Journal article
Phenotypic consequences of slc25a40-abcb1 fusions beyond drug resistance in high-grade serous ovarian cancer
DOI: 10.3390/cancers132256442021
Journal article
Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma
DOI: 10.1371/journal.pcbi.1008755